PreveCeutical Announces Change of Auditors
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) has announced a change in its auditing firm. The company's board of directors has accepted the resignation of Smythe LLP as their former auditor and appointed Davidson & Company LLP as the successor auditor, effective December 18, 2024. The new auditor will serve until the company's next annual general meeting of shareholders.
The company confirms there were no reservations in the former auditor's reports during their tenure, and no reportable events exist between PreveCeutical and Smythe LLP. The required documentation, including the Notice of Change of Auditor and letters from both auditing firms, has been reviewed by the audit committee and board of directors and will be filed on SEDAR.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) ha annunciato un cambio nel suo studio di revisione. Il consiglio di amministrazione dell'azienda ha accettato le dimissioni di Smythe LLP come loro precedente revisore e ha nominato Davidson & Company LLP come revisore successore, con effetto dal 18 dicembre 2024. Il nuovo revisore rimarrà in carica fino alla prossima assemblea annuale degli azionisti.
L'azienda conferma che non ci sono state riserve nei rapporti del precedente revisore durante il loro mandato, e non ci sono eventi da segnalare tra PreveCeutical e Smythe LLP. La documentazione richiesta, inclusa la Notifica di Cambio di Revisore e le lettere di entrambi gli studi di revisione, è stata esaminata dal comitato di revisione e dal consiglio di amministrazione e sarà archiviata su SEDAR.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) ha anunciado un cambio en su firma de auditoría. La junta directiva de la compañía ha aceptado la renuncia de Smythe LLP como su auditor anterior y ha nombrado a Davidson & Company LLP como el auditor sucesor, con efecto a partir del 18 de diciembre de 2024. El nuevo auditor servirá hasta la próxima junta anual de accionistas.
La compañía confirma que no hubo reservas en los informes del auditor anterior durante su mandato, y no existen eventos reportables entre PreveCeutical y Smythe LLP. La documentación requerida, incluida la Notificación de Cambio de Auditor y cartas de ambas firmas de auditoría, ha sido revisada por el comité de auditoría y la junta directiva y será presentada en SEDAR.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF)는 감사 회사를 변경했다고 발표했습니다. 회사의 이사회는 이전 감사인으로 Smythe LLP의 사임을 수락하고 Davidson & Company LLP를 후임 감사인으로 임명했습니다. 이는 2024년 12월 18일부터 효력이 발생합니다. 새로운 감사인은 회사의 다음 주주 총회까지 서비스를 제공할 예정입니다.
회사는 이전 감사인의 재임 중 보고서에 예약이 없었음을 확인하며, PreveCeutical과 Smythe LLP之间의 보고할 수 있는 사건은 없다고 밝혔습니다. 감사 변경 통지서 및 두 감사 회사의 서신을 포함한 필요한 문서가 감사 위원회와 이사회에 의해 검토되었으며, SEDAR에 제출될 것입니다.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) a annoncé un changement de son cabinet d'audit. Le conseil d'administration de la société a accepté la démission de Smythe LLP en tant qu'ancien auditeur et a nommé Davidson & Company LLP en tant qu'auditeur successeur, avec effet au 18 décembre 2024. Le nouvel auditeur exercera jusqu'à la prochaine assemblée générale annuelle des actionnaires.
La société confirme qu'il n'y avait aucune réserve dans les rapports de l'ancien auditeur durant son mandat, et qu'aucun événement à signaler n'existe entre PreveCeutical et Smythe LLP. La documentation requise, y compris l'avis de changement d'auditeur et les lettres des deux cabinets d'audit, a été examinée par le comité d'audit et le conseil d'administration et sera déposée sur SEDAR.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) hat einen Wechsel seiner Wirtschaftsprüfungsgesellschaft angekündigt. Der Vorstand des Unternehmens hat den Rücktritt von Smythe LLP als bisheriger Prüfer akzeptiert und Davidson & Company LLP als Nachfolgeprüfer bestellt, wirksam ab dem 18. Dezember 2024. Der neue Prüfer wird bis zur nächsten ordentlichen Hauptversammlung der Aktionäre tätig sein.
Das Unternehmen bestätigt, dass es während der Amtszeit des ehemaligen Prüfers keine Vorbehalte in den Berichten gab und zwischen PreveCeutical und Smythe LLP keine meldepflichtigen Ereignisse bestehen. Die erforderlichen Unterlagen, einschließlich der Mitteilung über den Wechsel des Prüfers und Briefe beider Wirtschaftsprüfungsgesellschaften, wurden vom Prüfungsausschuss und dem Vorstand überprüft und werden bei SEDAR eingereicht.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that the Company has changed its auditor from Smythe LLP, Certified Public Accountants ("Former Auditor") to Davidson & Company LLP, Certified Professional Accounts ("Successor Auditor") effective December 18, 2024.
PreveCeutical's board of directors accepted the resignation of the Former Auditor and appointed the Successor Auditor as the new auditor of the Company effective December 18, 2024, and to hold office until the close of the Company's next annual general meeting of shareholders.
There were no reservations in the Former Auditor's audit reports for any financial period during which the Former Auditor was the Company's auditor. There are no "reportable events" (as the term is defined in National Instrument 51-102 - Continuous Disclosure Obligations) between the Company and the Former Auditor.
In accordance with National Instrument 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the Company's audit committee and board of directors and will be filed on SEDAR accordingly.
About PreveCeutical
PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com
Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's plans relating to the development, clinical trials and commercialization of its products; and management expectations that it will miss the filing deadline for the Annual Filings and the Company's ability to file the Annual Filings within the time period described herein.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to execute its business plans as intended; the Company being unable to file the Annual Filings in the proposed timeframe; recent market volatility; and the state of the financial markets for the Company's securities.
In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to execute its business plans as intended; the Company will be able to file the Annual Filings in the proposed time frame.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234369
FAQ
When did PreveCeutical (PRVCF) change its auditor?
Who is PreveCeutical's (PRVCF) new auditor?
Were there any reservations in PreveCeutical's (PRVCF) previous audit reports?
Are there any reportable events between PreveCeutical (PRVCF) and its former auditor?
